Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy
Top Cited Papers
- 15 July 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Materials
- Vol. 11 (10), 895-905
- https://doi.org/10.1038/nmat3355
Abstract
The tumour microenvironment thwarts conventional immunotherapy through multiple immunologic mechanisms, such as the secretion of the transforming growth factor-β (TGF-β), which stunts local tumour immune responses. Therefore, high doses of interleukin-2 (IL-2), a conventional cytokine for metastatic melanoma, induces only limited responses. To overcome the immunoinhibitory nature of the tumour microenvironment, we developed nanoscale liposomal polymeric gels (nanolipogels; nLGs) of drug-complexed cyclodextrins and cytokine-encapsulating biodegradable polymers that can deliver small hydrophobic molecular inhibitors and water-soluble protein cytokines in a sustained fashion to the tumour microenvironment. nLGs releasing TGF-β inhibitor and IL-2 significantly delayed tumour growth, increased survival of tumour-bearing mice, and increased the activity of natural killer cells and of intratumoral-activated CD8+ T-cell infiltration. We demonstrate that the efficacy of nLGs in tumour immunotherapy results from a crucial mechanism involving activation of both innate and adaptive immune responses.Keywords
This publication has 48 references indexed in Scilit:
- The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayersNature Materials, 2011
- Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responsesNature Materials, 2011
- Autonomous in Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive NanovalvesJournal of the American Chemical Society, 2010
- Engulfing tumors with synthetic extracellular matrices for cancer immunotherapyBiomaterials, 2009
- Opposing Effects of TGF-β and IL-15 Cytokines Control the Number of Short-Lived Effector CD8+ T CellsImmunity, 2009
- Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathologyNature Medicine, 2008
- Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug DeliveryACS Nano, 2008
- Chapter 8 The Role of NKT Cells in Tumor ImmunityAdvances in Cancer Research, 2008
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProceedings of the National Academy of Sciences of the United States of America, 2006
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004